Clinical Trial Detail

NCT ID NCT01371981
Title Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Etoposide

Sorafenib

Cytarabine + Etoposide

Cytarabine + Mitoxantrone

Asparaginase + Cytarabine

Bortezomib

Age Groups: adult child

No variant requirements are available.